NRSN (NeuroSense Therapeutics) Selling, General, & Admin. Expense: $4.86 Mil (TTM As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
31 GF Score
Price $0.71
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Selling, General, & Admin. Expense?

NeuroSense Therapeutics NRSN +0.28% 31 Selling, General, & Admin. Expense is $4.86 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. NeuroSense Therapeutics's selling, general, & admin. expense for the six months ended in Dec. 2025 was $2.67 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was $4.86 Mil.


NeuroSense Therapeutics  (NAS:NRSN) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


NeuroSense Therapeutics Selling, General, & Admin. Expense Related Terms


NeuroSense Therapeutics Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Selling, General, & Admin. Expense Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 2.51 4.97 4.78 4.20 4.86

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.22 2.29 1.91 2.19 2.67

NRSN vs SER, PVCT, IGC: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroSense Therapeutics Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Selling, General, & Admin. Expense falls into.


NRSN
31GF Score
NeuroSense Therapeutics Ltd NRSN
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $4.86 Mil mean?
NeuroSense Therapeutics (NRSN) has a Selling, General, & Admin. Expense of $4.86 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Selling, General, & Admin. Expense too high?
NeuroSense Therapeutics' current Selling, General, & Admin. Expense is $4.86 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Selling, General, & Admin. Expense compare to SER and PVCT?
NeuroSense Therapeutics' Selling, General, & Admin. Expense of $4.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Selling, General, & Admin. Expense is $4.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Selling, General, & Admin. Expense of $4.86 Mil. The current Selling, General, & Admin. Expense is $4.86 Mil. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Selling, General, & Admin. Expense is $4.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score

Get the complete analysis for NRSN

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price